The KRT23 antibody targets keratin 23 (KRT23), a member of the keratin family of intermediate filament proteins. Keratins are critical for maintaining epithelial cell structure, integrity, and stress response. KRT23. specifically categorized as a type I acidic keratin, is encoded by the *KRT23* gene located on chromosome 17q21.2. Unlike "hard" keratins in hair or nails, KRT23 is a "soft" keratin expressed in glandular and mucosal epithelial tissues, including the gastrointestinal tract, liver, and pancreas.
KRT23 gained attention due to its upregulated expression in certain cancers, particularly colorectal cancer (CRC), hepatocellular carcinoma (HCC), and cholangiocarcinoma. Studies suggest it may serve as a biomarker for tumor progression, as elevated KRT23 levels correlate with poor prognosis, metastasis, and chemoresistance. Its overexpression is linked to NF-κB pathway activation, promoting cell proliferation and survival. Additionally, KRT23 is implicated in inflammatory conditions like ulcerative colitis, where its expression increases during mucosal repair.
KRT23 antibodies are primarily used in research to detect protein expression via techniques like immunohistochemistry (IHC), Western blotting, or immunofluorescence. These tools help elucidate KRT23's role in disease mechanisms, diagnostic potential, and therapeutic targeting. Commercial antibodies are validated for specificity across human and mouse tissues, aiding translational studies. Ongoing research explores KRT23's dual role in epithelial homeostasis and pathology, highlighting its value in both basic science and clinical applications.